Mental Health Clinics in Columbus, MT Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Compass Mental Health Foundation Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 612 E Pike Ave, Columbus, MT 59019 Phone: 406-780-0528 |
Bobbi Garr, Pllc Social Worker - Clinical Medicare: Medicare Enrolled Practice Location: 612 E Pike Ave, Columbus, MT 59019 Phone: 406-530-7238 |
News Archive
FDA and FSIS announce joint public meeting to prevent foodborne illness
A joint public meeting focused on improving the system for tracing of food products and ingredients that are causing illness outbreaks or presenting other risks to the health of consumers was announced today by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services and the Food Safety and Inspection Service (FSIS) of the U.S. Department of Agriculture (USDA).
Regeneron submits VEGF Trap-Eye BLA to FDA for treatment of wet AMD
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
Poor, less educated patients are less likely to receive opioid pain medications in emergency rooms
Patients in moderate to severe pain in emergency rooms across the U.S. are less likely to receive opioid pain medications if they are black, Hispanic, poor, or have less education, compared to more affluent patients, according to a University of Rochester Medical Center study reported in the Journal of General Internal Medicine.
Ocular drug delivery: DSM awarded membership in PANOPTES EU Funded Consortium
DSM, a global leader in biomedical materials sciences, today announced that it is contributing proprietary knowledge in the preparation of tailored amino acid-based polymers and offering use of processing facilities that will produce an innovative step change in the sustained delivery of drug molecules. The PANOPTES consortium's goal is to research and develop novel drug delivery technology for the posterior eye segment. This partnership further validates the innovative properties of DSM's polyesteramide (PEA) biomaterials as a superior drug delivery technology.
› Verified 2 days ago